CDT — CDT Equity Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1896212 ·
Last close
$2.49
Market Cap
$1.96M
52W High
$3.90
52W Low
$0.30
ADV30
116,523
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,656,000 | -4,063,000 | 127,087,000 | 97,000 | 21,636,000 |
| Dec 2025 | 0 | — | -21,156,000 | -21,325,000 | 5,650,000 | 1,509,000 | 12,820,000 |
| Sep 2025 | 0 | — | -6,936,000 | -7,118,000 | 8,552,000 | 3,838,000 | 4,274,000 |
| Jun 2025 | 0 | — | -4,952,000 | -6,028,000 | 7,989,000 | 3,332,000 | 4,460,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,520,000
Investing CF
$-404,000
Financing CF
$11,982,000
CapEx
$-2,403,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-23379.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,388,000
Inventory
—
Receivables
$146,000
ST Investments
—
EBIT TTM
$-38,341,000
Pretax Income TTM
$-38,533,000
Interest Exp TTM
$192,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,660,000 | -39,224,000 | 5,650,000 | 12,820,000 | — | -15,555,000 |
| Dec 2024 | 0 | -15,105,000 | -17,802,000 | 4,193,000 | 10,986,000 | — | -9,682,000 |
| Dec 2023 | 0 | -5,262,000 | -535,000 | 7,224,000 | 7,681,000 | — | -7,725,000 |
| Dec 2022 | 0 | -3,160,000 | -4,887,000 | 5,000 | 10,094,000 | — | -2,266,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTIX | Protagenic Therapeutics, Inc.\new | $1.97M | $1.09 | — |
| SXTC | China SXT Pharmaceuticals, Inc. | $2.03M | $3.80 | — |
| DCOY | Decoy Therapeutics Inc. | $2.04M | $3.11 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2.06M | $3.52 | — |
| AGNPF | Grey Matters Health Inc. | $1.80M | $0.33 | — |
News headlines (Yahoo Finance, 1h cache)
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
2026-07-20 12:30 · Yahoo
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
2026-06-26 12:30 · Yahoo
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
2026-06-18 12:30 · Yahoo
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
2026-05-11 20:01 · Yahoo
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
2026-05-07 12:30 · Yahoo
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
2026-05-06 12:30 · Yahoo
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
2026-04-16 12:30 · Yahoo
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
2026-04-07 12:30 · Yahoo
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
2026-08-25 09:00 · Yahoo
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
2026-08-03 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.